RNTX NASDAQ
Rein Therapeutics Inc.
1W: -11.2%
1M: -45.6%
3M: -10.4%
YTD: -20.4%
1Y: -55.0%
$0.97
-0.02 (-2.40%)
Weekly Expected Move ±18.3%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$27.9M
52W Range0.98-2.21
Volume986,047
Avg Volume533,278
Beta1.42
Dividend—
Analyst Ratings
Company Info
CEOJames Brian Windsor
Employees11
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2017-06-29
Websitereintx.com
12407 N. Mopac Expy.
Austin, TX 78758
US
Austin, TX 78758
US
737 802 1989
About Rein Therapeutics Inc.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Latest News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Rein Therapeutics stock dips after pricing $50M share offering
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WINDSOR JAMES BRIAN | A-Award | 150,000 | $1.17 | 2026-05-08 |
| WINDSOR JAMES BRIAN | P-Purchase | 25,000 | $1.00 | 2026-04-30 |
| Voss Capital, LP | P-Purchase | 104,183 | $1.22 | 2025-11-14 |
| Voss Capital, LP | P-Purchase | 178,392 | $1.39 | 2025-10-28 |
| Voss Capital, LP | P-Purchase | 92,642 | $1.37 | 2025-10-27 |